Literature DB >> 21163532

Disruption of the alternative pathway convertase occurs at the staphylococcal surface via the acquisition of factor H by Staphylococcus aureus.

Julia A Sharp1, Kenji M Cunnion.   

Abstract

Staphylococcus aureus is a significant human pathogen that causes skin-structure, invasive, and hospital-associated infections worldwide. The complement system is vital to innate defense against many bacterial infections. As shown with other pathogens, mechanisms for circumventing complement attack may include recruitment of the complement regulatory protein factor H (fH). In the present study, we show that S. aureus binds fH in a dose-dependent and time-dependent manner. Interestingly, this interaction does not require complement activation nor C3-fragment presence and occurs efficiently in the absence of other serum components suggesting a mechanism other than bridging between intermediary molecules. However, fH binding is greater when incubated with normal human serum compared to heat-inactivated serum, which suggests that complement activation may enhance fH binding. S. aureus-bound fH was found to inhibit the alternative pathway through disruption of the alternative pathway C3 convertase as shown by an increase in Bb release and a decrease in total C3-fragment deposition. Furthermore, S. aureus-bound fH retains cofactor activity for factor-I mediated cleavage of C3b. These studies show that the acquisition of fH to the S. aureus surface inhibits complement-mediated opsonization via disruption of the alternative pathway convertase; thus, we report an immune-evasion mechanism not previously described for S. aureus.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21163532      PMCID: PMC3015216          DOI: 10.1016/j.molimm.2010.11.014

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  34 in total

1.  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

Authors: 
Journal:  Am J Infect Control       Date:  2004-12       Impact factor: 2.918

Review 2.  Immune evasion by staphylococci.

Authors:  Timothy J Foster
Journal:  Nat Rev Microbiol       Date:  2005-12       Impact factor: 60.633

3.  Serum complement factor I decreases Staphylococcus aureus phagocytosis.

Authors:  Kenji M Cunnion; E Stephen Buescher; Pamela S Hair
Journal:  J Lab Clin Med       Date:  2005-11

4.  Morbidity and mortality of Staphylococcal bacteremia in children.

Authors:  Hana Hakim; Joseph M Mylotte; Howard Faden
Journal:  Am J Infect Control       Date:  2007-03       Impact factor: 2.918

5.  Identification of residues within the 727-767 segment of human complement component C3 important for its interaction with factor H and with complement receptor 1 (CR1, CD35).

Authors:  A E Oran; D E Isenman
Journal:  J Biol Chem       Date:  1999-02-19       Impact factor: 5.157

6.  Role of the hypervariable region in streptococcal M proteins: binding of a human complement inhibitor.

Authors:  E Johnsson; K Berggård; H Kotarsky; J Hellwage; P F Zipfel; U Sjöbring; G Lindahl
Journal:  J Immunol       Date:  1998-11-01       Impact factor: 5.422

7.  Cleavage of complement C3b to iC3b on the surface of Staphylococcus aureus is mediated by serum complement factor I.

Authors:  K M Cunnion; P S Hair; E S Buescher
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

8.  Role of complement receptors 1 and 2 (CD35 and CD21), C3, C4, and C5 in survival by mice of Staphylococcus aureus bacteremia.

Authors:  Kenji M Cunnion; Daniel K Benjamin; C Garren Hester; Michael M Frank
Journal:  J Lab Clin Med       Date:  2004-06

9.  Variation in the expression of cell wall proteins of Staphylococcus aureus grown on solid and liquid media.

Authors:  A L Cheung; V A Fischetti
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

Review 10.  Understanding how leading bacterial pathogens subvert innate immunity to reveal novel therapeutic targets.

Authors:  Victor Nizet
Journal:  J Allergy Clin Immunol       Date:  2007-07       Impact factor: 10.793

View more
  6 in total

1.  New potential role of serum apolipoprotein E mediated by its binding to clumping factor A during Staphylococcus aureus invasive infections to humans.

Authors:  Walid F Elkhatib; Pamela S Hair; Julius O Nyalwidhe; Kenji M Cunnion
Journal:  J Med Microbiol       Date:  2015-04       Impact factor: 2.472

2.  The extracellular adherence protein from Staphylococcus aureus inhibits the classical and lectin pathways of complement by blocking formation of the C3 proconvertase.

Authors:  Jordan L Woehl; Daphne A C Stapels; Brandon L Garcia; Kasra X Ramyar; Andrew Keightley; Maartje Ruyken; Maria Syriga; Georgia Sfyroera; Alexander B Weber; Michal Zolkiewski; Daniel Ricklin; John D Lambris; Suzan H M Rooijakkers; Brian V Geisbrecht
Journal:  J Immunol       Date:  2014-11-07       Impact factor: 5.422

3.  Identification of peptidic inhibitors of the alternative complement pathway based on Staphylococcus aureus SCIN proteins.

Authors:  Brady J Summers; Brandon L Garcia; Jordan L Woehl; Kasra X Ramyar; Xiaolan Yao; Brian V Geisbrecht
Journal:  Mol Immunol       Date:  2015-06-04       Impact factor: 4.407

4.  Staphylococcus aureus surface protein SdrE binds complement regulator factor H as an immune evasion tactic.

Authors:  Julia A Sharp; Charlene G Echague; Pamela S Hair; Michael D Ward; Julius O Nyalwidhe; Joan A Geoghegan; Timothy J Foster; Kenji M Cunnion
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

Review 5.  Host- and microbe determinants that may influence the success of S. aureus colonization.

Authors:  Mona Johannessen; Johanna E Sollid; Anne-Merethe Hanssen
Journal:  Front Cell Infect Microbiol       Date:  2012-05-04       Impact factor: 5.293

6.  A Factor H-Fc fusion protein increases complement-mediated opsonophagocytosis and killing of community associated methicillin-resistant Staphylococcus aureus.

Authors:  Megan A G Sage; Katelyn D Cranmer; Michele L Semeraro; Shelby Ma; Elena V Galkina; Y Tran; Keith L Wycoff; Julia A Sharp
Journal:  PLoS One       Date:  2022-03-24       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.